TELMIKIND BETA 50MG

About

TELMIKIND BETA 50MG combines Telmisartan, an angiotensin receptor blocker (ARB), with Metoprolol, a selective beta-1 adrenergic blocker. This medication is primarily indicated for the treatment of hypertension and other cardiovascular conditions where both an ARB and a beta-blocker are beneficial. Telmisartan works by blocking the effects of angiotensin II, leading to vasodilation and reduced blood pressure. Metoprolol reduces heart rate, myocardial contractility, and cardiac output by selectively blocking beta-1 receptors in the heart.

The combination provides a comprehensive approach to managing blood pressure and improving cardiac function, particularly in patients who may also benefit from heart rate control or have conditions like angina or post-myocardial infarction. This dual action helps to reduce the workload on the heart and improve overall cardiovascular outcomes.

Uses

• Management of essential hypertension
• Treatment of angina pectoris
• Adjunct therapy post-myocardial infarction
• Reduction of cardiovascular mortality and morbidity

Directions For Use

Take orally once daily, preferably with food, or as advised by your healthcare provider.

Benefits

• Provides effective and sustained blood pressure control
• Helps to reduce heart rate and myocardial oxygen demand
• Reduces the risk of cardiovascular events and mortality
• Offers a dual mechanism for comprehensive cardiac protection
• Convenient once-daily dosing enhances patient compliance
• Beneficial for patients with co-existing angina or post-MI status

Side Effects

• Bradycardia (slow heart rate)
• Dizziness
• Fatigue
• Cold extremities
• Nausea
• Diarrhea
• Shortness of breath
• Insomnia
• Depression
• Erectile dysfunction
• Rash
• Muscle weakness

Safety Measures

• Alcohol - Alcohol may enhance the hypotensive effects and increase the risk of dizziness or drowsiness. Avoid excessive alcohol consumption.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters, due0 to potential fetal harm from telmisartan.
• Breastfeeding - Not recommended during breastfeeding as both components may pass into breast milk and could affect the infant.
• Liver - Use with caution in patients with hepatic impairment. Dosage adjustment may be necessary, and close monitoring is advised.
• Kidney - Use with caution in patients with renal impairment. Regular monitoring of kidney function and serum potassium levels is recommended.
• Lung - Contraindicated in severe asthma, severe COPD, or other severe obstructive airway diseases due to the beta-blocker component.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.